Risk of cervical HPV infection and prevalence of vaccine-type and other high-risk HPV types among sexually active teens and young women (13–26 years) enrolled in the VALHIDATE study

HPV vaccination is expected to reduce the incidence of cervical cancer. The greatest and the earliest health gains will be ensured by high vaccine coverage among all susceptible people. The high costs and the risk of a reduced cost/effectiveness ratio in sexually active girls still represent the mai...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Hum Vaccin Immunother
Main Authors: Orlando, Giovanna, Fasolo, Michela, Mazza, Francesca, Ricci, Elena, Esposito, Susanna, Frati, Elena, Zuccotti, Gian Vincenzo, Cetin, Irene, Gramegna, Maria, Rizzardini, Giuliano, Tanzi, Elisabetta, group, VALHIDATE study
Format: Artigo
Sprog:Inglês
Udgivet: Taylor & Francis 2014
Fag:
Research Paper
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4896517/
https://ncbi.nlm.nih.gov/pubmed/24423757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.27682
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker